IP Library Granted Patent US 11,535,874
Granted Patent B2
US 11,535,874 · App. 14/436,722 · Granted Dec 27, 2022

Microorganisms and methods for enhancing the availability of reducing equivalents in the presence of methanol, and for producing succinate related thereto

Inventors: Anthony P. Burgard (Bellefonte, PA); Robin E. Osterhout (San Diego, CA); Stephen J. Van Dien (Encinitas, CA); Cara Ann Tracewell (Solana Beach, CA); Priti Pharkya (San Diego, CA); Stefan Andrae (San Diego, CA)
Assignee: Genomatica, Inc.
C12P7/46C07C55/10C07C59/235C08G63/00C12N9/0006C12N9/0028C12N9/1007C12N15/70C12N15/74C12N15/77C12N15/81C12N15/815C12P7/24C12Y101/01244C12Y105/0102
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,535,874
App. No.
14/436,722
Granted
Dec 27, 2022
Kind
B2
Abstract

Provided herein is a non-naturally occurring microbial organism (NNOMO) having a methanol metabolic pathway (MMP) that can enhance the availability of reducing equivalents in the presence of methanol. Such reducing equivalents can be used to increase the product yield of organic compounds produced by the microbial organism, such as succinate. Also provided herein are methods for using such an organism to produce succinate.

Claims (69)

1. A non-naturally occurring microbial organism comprising:

(a) a methanol metabolic pathway (MMP), wherein said non-naturally occurring microbial organism comprises at least one exogenous nucleic acid encoding a MMP enzyme expressed in a sufficient amount for biosynthesis of succinate, and wherein said MMP comprises:

(i) a methanol dehydrogenase (EM9) from bacteria,

(ii) an EM9 from bacteria and a formaldehyde activating enzyme (EM10), or

(iii) a methanol methyltransferase (EM1) and a methylenetetrahydrofolate reductase (EM2), and

wherein EM9 converts methanol to formaldehyde,

wherein EM10 converts formaldehyde to methylene-tetrahydrofolate (THF),

wherein EM1 converts methanol to methyl-THF, and

wherein EM2 converts methyl-THF to methylene-THF;

(b) a succinate pathway (SucP); and

(c) a formaldehyde assimilation pathway (FAP), wherein said non-naturally occurring microbial organism comprises at least one exogenous nucleic acid encoding a FAP enzyme and wherein said FAP comprises:

(i) a hexulose-6-phosphate synthase (EF1) and a 6-phospho-3-hexuloisomerase (EF2), or

(ii) a dihydroxyacetone synthase (EF3) or a dihydroxyacetone kinase (EF4);

wherein EF1 converts formaldehyde and D-ribulose-5-phosphate to hexulose-6-phosphate,

wherein EF2 converts hexulose-6-phosphate to fructose-6-phosphate,

wherein EF3 converts formaldehyde and xylulose-6-phosphate to dihydroxyacetone, and

wherein EF4 converts dihydroxyacetone to dihydroxyacetone-phosphate; and

wherein said non-naturally occurring microbial organism comprises an Escherichia coli or Saccharomyces cerevisiae.

2. The non-naturally occurring microbial organism of claim 1 , wherein said non-naturally occurring microbial organism comprises at least one nucleic acid encoding a SucP enzyme (SucPE) expressed in a sufficient amount to produce succinate, wherein said SucP comprises:

(a) a phosphoenolpyruvate (PEP) carboxylase (ES1A) or a PEP carboxykinase (ES1 B), a malate dehydrogenase (ES3), a fumarase (ES5), and a fumarate reductase (ES6);

(b) a pyruvate carboxylase (ES2), an ES3, an ES5, and an ES6; or

(c) a malic enzyme (ES4), an ES5, and an ES6;

wherein ES1A and ES1B convert PEP to oxaloacetate,

wherein ES2 converts pyruvate to oxaloacetate,

wherein ES3 converts oxaloacetate to malate,

wherein ES4 converts pyruvate to malate,

wherein ES5 converts malate to fumarate, and

wherein ES6 converts fumarate to succinate.

3. The non-naturally occurring microbial organism of claim 1 , wherein:

(a) said MMP comprises:

(i) an EM9 from bacteria, a methylenetetrahydrofolate dehydrogenase (EM3), a methenyltetrahydrofolate cyclohydrolase (EM4), and a formyltetrahydrofolate deformylase (EM5);

(ii) an EM9 from bacteria, an EM3, an EM4, and a formyltetrahydrofolate synthetase (EM6);

(iii) an EM9 from bacteria and a formaldehyde dehydrogenase (EM11);

(iv) an EM9 from bacteria, a S-(hydroxymethyl)glutathione synthase (EM12), a glutathione-dependent formaldehyde dehydrogenase (EM13), and a S-formylglutathione hydrolase (EM14);

(v) an EM9 from bacteria, an EM13, and an EM14;

(vi) an EM9 from bacteria, an EM10, an EM3, an EM4, and an EM5;

(vii) an EM9 from bacteria, an EM10, an EM3, an EM4, and an EM6;

(viii) an EM1, an EM2, an EM3, an EM4, and an EM5; or

(ix) an EM1, an EM2, an EM3, an EM4 and an EM6;

wherein EM3 converts methylene-THF to methenyl-THF,

wherein EM4 converts methenyl-THF to formyl-THF,

wherein EM5 and EM6 convert formyl-THF to formate,

wherein EM11 converts formaldehyde to formate,

wherein EM12 converts formaldehyde to S-hydroxymethylglutathione,

wherein EM13 converts S-hydroxymethylglutathione to S-formylglutathione, and

wherein EM14 converts S-formylglutathione to formate.

4. The non-naturally occurring microbial organism of claim 1 , wherein:

said non-naturally occurring microbial organism comprises two exogenous nucleic acids, each encoding a FAP enzyme.

5. The non-naturally occurring microbial organism of claim 1 , wherein:

(a) said at least one exogenous nucleic acid is a heterologous nucleic acid; and/or

(b) said non-naturally occurring microbial organism is in a substantially anaerobic culture medium.

6. A method for producing succinate, comprising:

culturing the non-naturally occurring microbial organism of claim 1 under conditions and for a sufficient period of time to produce succinate.

7. The method of claim 6 , wherein said method further comprises separating said succinate from other components in said culture.

8. The method of claim 7 , wherein said separating comprises extraction, continuous liquid-liquid extraction, pervaporation, membrane filtration, membrane separation, reverse osmosis, electrodialysis, distillation, crystallization, centrifugation, extractive filtration, ion exchange chromatography, size exclusion chromatography, adsorption chromatography, or ultrafiltration.

9. The method of claim 6 , wherein said culturing is in a culture medium comprising glucose.

10. The non-naturally occurring microbial organism of claim 1 , wherein said non-naturally occurring microbial organism is Saccharomyces cerevisiae and is Crabtree positive.

11. The non-naturally occurring microbial organism of claim 1 , wherein said MMP comprises an EM9 from bacteria.

12. The non-naturally occurring microbial organism of claim 1 , wherein said MMP comprises an EM9 from bacteria and EM10.

13. The non-naturally occurring microbial organism of claim 1 , wherein said MMP comprises an EM1 and an EM2.

14. The non-naturally occurring microbial organism of claim 1 , wherein said FAP comprises an EF1 and an EF2.

15. The non-naturally occurring microbial organism of claim 1 , wherein said FAP comprises an EF3 or an EF4.

16. The non-naturally occurring microbial organism of claim 2 , wherein said non-naturally occurring microbial organism comprises one, two, three, or four nucleic acids, each encoding a SucPE.

17. The non-naturally occurring microbial organism of claim 2 , wherein said at least one nucleic acid encoding a succinate enzyme is an exogenous or heterologous nucleic acid.

18. The non-naturally occurring microbial organism of claim 3 , wherein said MMP further comprises a formate dehydrogenase (EM8), a formate hydrogen lyase (EM15), or a hydrogenase (EM16);

wherein EM8 converts formate to reducing equivalents,

wherein EM15 converts formate to reducing equivalents, and

wherein EM16 converts hydrogen gas to reducing equivalents.

19. The non-naturally occurring microbial organism of claim 3 , wherein said non-naturally occurring microbial organism comprises two, three, four, five, six, or seven exogenous nucleic acids, each encoding a MMP enzyme.

Assignments (4)
SECURITY INTEREST Recorded Feb 10, 2026
From: GENOMATICA, INC.
To: AGAIN BIO APS
Reel/Frame 074708/0001 →
SECURITY INTEREST Recorded Dec 9, 2025
From: GENOMATICA, INC.
To: NOVO HOLDINGS A/S, AS COLLATERAL AGENT
Reel/Frame 073915/0027 →
SECURITY INTEREST Recorded Jun 2, 2025
From: GENOMATICA, INC.
To: OXFORD FINANCE LLC
Reel/Frame 071471/0770 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 11, 2016
From: BURGARD, ANTHONY P.; OSTERHOUT, ROBIN E.; VAN DIEN, STEPHEN J.; TRACEWELL, CARA ANN; PHARKYA, PRITI; ANDRAE, STEFAN
To: GENOMATICA, INC.
Reel/Frame 037711/0080 →